International Journal of Biological Sciences

Impact factor
3.873

ISSN 1449-2288

News feeds of IJBS published articles
My Manuscript
My Account

Journal of Biomedicinenew

Theranostics

International Journal of Medical Sciences

Journal of Cancer

Oncomedicine

Journal of Genomics

Journal of Bone and Joint Infection (JBJI)

Nanotheranostics

Journal of Genomics now in PubMed/PubMed Central. Submit manuscript...

PubMed Central Indexed in Journal Impact Factor

Int J Biol Sci 2017; 13(4):471-479. doi:10.7150/ijbs.16290

Research Paper

Dipalmitoylphosphatidic acid inhibits tumor growth in triple-negative breast cancer

Qian-Qian Zhang1✉, Jian Chen1, Da-Lei Zhou1, You-Fa Duan1, Cui-Ling Qi1, Jiang-Chao Li1, Xiao-Dong He1, Min Zhang1, Yong-Xia Yang2, Lijing Wang1✉

1. Vascular Biology Research Institute, School of Basic Course, Guangdong Pharmaceutical University, Guangzhou 510006, China;
2. School of Basic Course, Guangdong Pharmaceutical University, Guangzhou 510006, China.

Abstract

Triple-negative breast cancer (TNBC) is a subtype of breast cancer with a poor prognosis, accounting for approximately 12-24% of breast cancer cases. Accumulating evidence has indicated that there is no effective targeted therapy available for TNBC. Dipalmitoylphosphatidic acid (DPPA) is a bioactive phospholipid. However, the function of DPPA in the growth of TNBC has not yet been studied. In this study, we employed TNBC cells and a subcutaneous tumor model to elucidate the possible effect of DPPA on tumor growth in TNBC. We showed that DPPA significantly inhibited tumor growth in the mouse subcutaneous tumor model and suppressed cell proliferation and angiogenesis in TNBC tumor tissues. This inhibition was mediated partly by suppressing the expression of cyclin B1 (CCNB1), which directly promoted the accumulation of cells in the G2 phase and arrested cell cycle progression in human TNBC. In addition, the inhibition of tumor growth by DPPA may also be mediated by the suppression of tumor angiogenesis in TNBC. This work provides initial evidence that DPPA might be vital as an anti-tumor drug to treat TNBC.

Keywords: Dipalmitoylphosphatidic acid, triple-negative breast cancer, growth, angiogenesis.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Zhang QQ, Chen J, Zhou DL, Duan YF, Qi CL, Li JC, He XD, Zhang M, Yang YX, Wang L. Dipalmitoylphosphatidic acid inhibits tumor growth in triple-negative breast cancer. Int J Biol Sci 2017; 13(4):471-479. doi:10.7150/ijbs.16290. Available from http://www.ijbs.com/v13p0471.htm